Merck (MRK) Net Income (2009 - 2026)
Merck's (MRK) quarterly Net Income came in at -$1.3 billion in Q2 2026, down 130.19% year-over-year from $4.4 billion in Q2 2025, and up 68.49% quarter-over-quarter from -$4.2 billion in Q1 2026.
Analysis
Merck (MRK) Net Income (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Net Income for 18 consecutive years, with -$1.3 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Net Income fell 130.19% year-over-year to -$1.3 billion in Q2 2026; TTM through Jun 2026 was $3.2 billion, a 80.7% decrease from a year earlier, with the FY2025 full-year figure at $18.3 billion, up 6.6% from the prior year.
- Net Income was -$1.3 billion for Q2 2026 at Merck, up from -$4.2 billion in the prior quarter.
- Over five years, Net Income peaked at $5.8 billion in Q3 2025 and troughed at -$6.0 billion in Q2 2023.
- A 5-year average of $2.5 billion and a median of $3.5 billion in 2022 frame the typical range for Net Income.
- Across the five-year window, Net Income sank 251.23% in 2023 and surged 405.38% in 2024, its largest moves.
- Over 5 years, Net Income stood at $3.0 billion in 2022, then tumbled by 140.62% to -$1.2 billion in 2023, then surged by 405.38% to $3.7 billion in 2024, then retreated by 20.89% to $3.0 billion in 2025, then sank by 145.14% to -$1.3 billion in 2026.
- The last three Net Income figures came in at -$1.3 billion (Q2 2026), -$4.2 billion (Q1 2026), and $3.0 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | -238.00 Mn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 2.16 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | -644.37 Mn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 585.61 Mn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 333.00 Mn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 144.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.34 Bn |
| Mar 31, 2026 | -4.24 Bn |
| Dec 31, 2025 | 2.96 Bn |
| Sep 30, 2025 | 5.79 Bn |
| Jun 30, 2025 | 4.43 Bn |
| Mar 31, 2025 | 5.09 Bn |
| Dec 31, 2024 | 3.74 Bn |
| Sep 30, 2024 | 3.16 Bn |
| Jun 30, 2024 | 5.46 Bn |
| Mar 31, 2024 | 4.77 Bn |
| Dec 31, 2023 | -1.23 Bn |
| Sep 30, 2023 | 4.75 Bn |
| Jun 30, 2023 | -5.97 Bn |
| Mar 31, 2023 | 2.83 Bn |
| Dec 31, 2022 | 3.02 Bn |
| Sep 30, 2022 | 3.25 Bn |
| Jun 30, 2022 | 3.95 Bn |
| Mar 31, 2022 | 4.31 Bn |
| Dec 31, 2021 | 3.76 Bn |
| Sep 30, 2021 | 4.57 Bn |